Eisai Eyes Longer-Lasting Stomach Acid Drug (Japan)
This article was originally published in PharmAsia News
Eisai Co. is working on a follow-up to Pariet, its drug for stomach ulcers, acid reflux, and related gastrointestinal problems. U.S. patents on Pariet, which is sold in America as Aciphex, expire in May 2013. Eisai hopes to have the new product ready by May 2013, when U.S. patents on the drug, which is marketed in the United States as Aciphex, expire. Eisai says the new drug will be longer-lasting and more effective than Pariet at blocking secretion of stomach acid at night. The third and final phase of clinical testing will begin as early as 2008 in the U.S. The company plans to apply for marketing approval in fiscal 2009. (Click here for more - May Require Paid Subscription
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.